Telomir Pharmaceuticals (NASDAQ:TELO) has secured $3 million in equity financing through a direct investment from The Bayshore Trust, the company's largest shareholder. The transaction, structured as a straight restricted common stock purchase with no warrants or convertible features, was completed at $3.00 per share—representing an 18% premium to Telomir's closing share price of $2.54 on the execution date.
This latest investment strengthens Telomir's financial position as it prepares to submit an Investigational New Drug (IND) application for its lead candidate, Telomir-1, in a rare disease indication by the end of the year. The financing follows a previous $1 million equity investment made in December 2024 and complements an existing $5 million non-dilutive line of credit that remains undrawn.
"We've now raised $4 million in equity and secured a $5 million credit line—all through affiliated entities on shareholder-friendly terms," said Erez Aminov, Chairman and CEO of Telomir. "These investments included no warrants, no discounts, and no toxic structures. Every financing decision we make is grounded in a long-term view of shareholder value."
Telomir-1: A Multi-Mechanism Approach to Age Reversal
Telomir-1 is an oral small molecule designed to address five fundamental biological drivers of aging and chronic disease: mitochondrial dysfunction, oxidative stress, calcium imbalance, toxic metal accumulation, and telomere shortening. This comprehensive approach positions the drug as a potential breakthrough in treating conditions associated with cellular aging.
Preclinical studies have demonstrated Telomir-1's ability to reverse the biological clock, improve mitochondrial energy production, reduce oxidative stress, correct calcium signaling pathways, protect against metal-induced toxicity, and support telomere lengthening and stabilization.
The compound has shown therapeutic potential across several critical indications in preclinical models:
- Progeria: Restored lifespan and normalized accelerated aging in a preclinical model of this rare genetic disorder
- Type 2 diabetes: Reversed insulin resistance, lowered fasting glucose, and improved glucose homeostasis in zebrafish models
- Wilson's disease: Protected cells from copper-induced toxicity while restoring mitochondrial function
- Oncology: Reduced tumor volume by approximately 50% in a prostate cancer mouse model
- Chemotherapy support: Prevented mortality when co-administered with Paclitaxel
- Retinal and neural protection: Demonstrated protection of human retinal cells from oxidative and metal stress conditions
Strategic Focus on Rare Diseases
Telomir plans to engage with the FDA through the Rare Disease Endpoint Advancement (RDEA) Pilot Program, which supports the development of novel clinical endpoints for underserved conditions. The company believes pursuing a rare disease indication provides a strategic entry point to demonstrate clinical impact efficiently.
"From an operational standpoint, our first goal is to submit our IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way," Aminov explained. "We believe pursuing a rare disease indication gives us a strategic entry point to demonstrate clinical impact and build broader value."
Based on preclinical results, Telomir is advancing Telomir-1 for multiple rare and high-value indications, including Progeria, Werner Syndrome, Wilson's Disease, Type 2 Diabetes, Autism Spectrum Disorder, Spasmodic Dysphonia, and Age-related Macular Degeneration.
Telomir-Ag2: Novel Antimicrobial Compound
In addition to Telomir-1, the company is developing Telomir-Ag2, a novel Silver(II) complex stabilized using Telomir's proprietary chelation platform. Silver(II) has historically shown strong antimicrobial potential but remained clinically impractical due to instability until Telomir's innovation.
Preclinical studies demonstrate that Telomir-Ag2 is active against several pathogens, including Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus, and methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA).
"Telomir-Ag2 may be the first stabilized Silver(II) compound viable for medical use," said Dr. Itzchak Angel, Chief Scientific Advisor of the Company. "Its broad-spectrum activity, especially against resistant strains, represents a major advancement in antimicrobial science."
The compound shows superior antimicrobial performance over Silver(I) in minimum inhibitory concentration assays, contains no sulfa-based compounds (minimizing allergic and cytotoxic risks), and has broad potential as a topical product for burn treatment, wound care, and surgical infection prevention. Telomir-Ag2 addresses a growing global market projected to exceed $30 billion across antimicrobial applications.
Financial Outlook and Development Timeline
With the additional $3 million investment, Telomir is positioned to advance its lead programs through critical development milestones. The company's immediate focus is submitting the IND for Telomir-1 by year-end, with plans to generate early human efficacy data in rare disease indications as efficiently as possible.
The shareholder-friendly financing structure, featuring premium pricing and no dilutive features, signals strong insider confidence in Telomir's scientific approach and commercial potential in both the age-reversal and antimicrobial markets.
